Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Biopsy-Guided arthritis treatment: a step toward personalized care?

NCT ID NCT05379322

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if analyzing joint tissue (synovial biopsies) could help doctors pick the best biologic drug for people with rheumatoid arthritis who had not responded to standard treatments. It planned to assign patients to either an anti-TNF or a JAK inhibitor based on their tissue type. However, the trial was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Started

Mar 2023

Expected to finish

Mar 2023

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject should be capable of consent * Age 18 and older * Classified as rheumatoid arthritis as per EULAR/ACR criteria 2010 * Failed one DMARD (Methotrexate, leflunomide, Sulfalsalazine, hydroxychloroquine) * Can be on steroid dose \<7.5mg * Quantiferon negative * Hepatitis B, C negative * No recent history (\<5y) of malignancy Exclusion Criteria: * Overlap syndrome * Previously treated with a biological medication * Heart failure NYHA III/IV * Active tuberculosis * Active infections * Previous history of DVT, PE, or Stroke * Other significant comorbidities that will prevent them from taking any biologic medication as per EULAR guidelines on treating rheumatoid arthritis 2020. * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abu Dhabi Stem Cells Center

    Abu Dhabi, Abu Dhabi Emirate, 4600, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.